59870-37-0

Basic information

• Product Name: Benzoyl chloride, 2,6-dibromo-
• Synonyms: 2,6-Dibrom-benzoylchlorid;2,6-dibromo-benzoyl chloride
• CAS NO: 59870-37-0
• Molecular Formula: C7H3Br2ClO
• Molecular Weight: 298.361
• Mol File: 59870-37-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzoyl chloride, 2,6-dibromo-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoyl chloride, 2,6-dibromo-(59870-37-0)
• EPA Substance Registry System: Benzoyl chloride, 2,6-dibromo-(59870-37-0)

Safety Data

• Hazardous Substances Data: 59870-37-0(Hazardous Substances Data)

Upstream product

• 601-84-3 2,6-dibromobenzoic acid 
• 67713-23-9 2,6-dibromobenzaldehyde 
• 96237-91-1 2,6-dibromobenzamide 
• 6575-12-8 2,6-dibromobenzonitrile 
• 608-30-0 2,6-dibromoaniline 

Downstream Products

• 96237-99-9 1-(2,6-dibromobenzoyl)-2-(p-nitrobenzoyl)hydrazine 
• 608-30-0 2,6-dibromoaniline 
• 1234380-77-8 2,6-dibromo-N-[2-(3-chloro-benzylsulfanyl)-ethyl]-benzamide 
• 1234380-78-9 2,6-dibromo-N-[2-(3-bromo-benzylsulfanyl)-ethyl]-benzamide 
• 1161124-35-1 C₁₇H₁₂Br₂N₂O₂ 
• 1214375-69-5 ethyl 2,6-dibromobenzoate 
• 59189-52-5 2,6-dibromobenzophenone 
• 96237-91-1 2,6-dibromobenzamide 

Relevant articles and documents

Noncovalent Interactions in Ir-Catalyzed C-H Activation: L-Shaped Ligand for Para-Selective Borylation of Aromatic Esters

An efficient strategy for the para-selective borylation of aromatic esters is described. For achieving high para-selectivity, a new catalytic system has been developed modifying the core structure of the bipyridine. It has been proposed that the L-shaped ligand is essential to recognize the functionality of the oxygen atom of the ester carbonyl group via noncovalent interaction, which provides an unprecedented controlling factor for para-selective C-H activation/borylation.

NOVEL COMPOUNDS

The present invention provides compounds of formula (I): a process for their preparation, to pharmaceutical compositions comprising the compounds and the preparation of said compositions, to intermediates and to use of the compounds for the manufacture of a medicament for therapeutic treatment, particularly for the treatment of inflammation, allergy and/or auto-immune conditions.